| 1.05 -0.02 (-1.87%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.32 | 1-year : | 1.37 |
| Resists | First : | 1.13 | Second : | 1.17 |
| Pivot price | 1.09  |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.07 |
MA(20) : | 1.11 |
| MA(100) : | 1.21 |
MA(250) : | 1.35 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 20.5 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 1.95 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PLRX ] has closed above bottom band by 5.1%. Bollinger Bands are 23% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.1 |
| Low: | 1.03 - 1.04 | 1.04 - 1.05 |
| Close: | 1.04 - 1.05 | 1.05 - 1.06 |
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Wed, 29 Jul 2026
PLRX|Pliant Therapeutics Inc|Price:1.075|Chg%:-0.005 - TradingKey
Tue, 28 Jul 2026
PLRX|Pliant Therapeutics Inc|Price:1.075|Chg%:-0.005 - TradingKey
Mon, 27 Jul 2026
Pliant Therapeutics Inc (PLRX) Income Statement - TradingKey
Mon, 27 Jul 2026
Pliant Therapeutics Inc (PLRX) Cash Flow - TradingKey
Mon, 13 Jul 2026
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors - GlobeNewswire
Mon, 13 Jul 2026
Pliant Therapeutics (PLRX) director files initial insider ownership statement - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 82 (%) |
| Shares Short | 2,820 (K) |
| Shares Short P.Month | 2,820 (K) |
| EPS | -1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -53.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -0.58 |
| PEG Ratio | 0 |
| Price to Book value | 0.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|